• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Tweardy Samuel David disposed of 631,316 shares (SEC Form 4)

    8/5/25 8:03:49 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TVRD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Tweardy Samuel David

    (Last) (First) (Middle)
    535 HAROLD AVENUE NE

    (Street)
    ATLANTA GA 30307

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Tvardi Therapeutics, Inc. [ TVRD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/07/2025 J(1) 315,658 D $0 0 I By Trust(1)
    Common Stock 07/07/2025 J(1) 315,658 D $0 0 I By Trust(1)
    Common Stock 315,658 I By Trust(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Reporting Person resigned as trustee of the family trust that directly holds the shares, as such the Reporting Person no longer retains any form beneficial ownership. The resignation does not constitute a sale of the of the shares and was permitted by the lock-up agreement by and between each family trust and the Issuer, dated December 17, 2024, and the shares remain subject to the lock-up agreement pursuant to the terms thereof.
    2. Securities are directly held by a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
    /s/ Samuel D. Tweardy 08/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TVRD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TVRD

    DatePrice TargetRatingAnalyst
    10/14/2025$5.00Overweight → Equal Weight
    Barclays
    10/14/2025Outperform → Mkt Perform
    Raymond James
    10/13/2025Overweight → Neutral
    Cantor Fitzgerald
    10/13/2025$78.00 → $4.00Overweight → Neutral
    Piper Sandler
    10/13/2025$61.00Overweight
    Barclays
    7/14/2025$62.00Outperform
    Raymond James
    7/11/2025$52.00Overweight
    Cantor Fitzgerald
    6/12/2025$78.00Overweight
    Piper Sandler
    More analyst ratings

    $TVRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    2/2/26 4:30:14 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    2/2/26 4:30:16 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    2/2/26 4:30:13 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tvardi Therapeutics to Participate in Upcoming Investor Conferences

    HOUSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will participate in the following upcoming investor conferences: JonesTrading C-Suite Fireside Chat SeriesDate: Wednesday, February 19, 2026Time: 11:00 AM ESTRegistration Link here Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate presentationDate: Wednesday, February 25, 2026Time: 10:40 AM ESTLocation: Virtual TD Cowen 46th Annual Health Care ConferenceFormat: Corporate prese

    2/12/26 8:00:00 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will deliver a company presentation during the 44th Annual J.P. Morgan Healthcare Conference, being held January 12th – 15th, 2026, in San Francisco, CA. During the presentation, Tvardi will discuss and provide additional context around the new Phase 2 REVERT IPF clinical trial data for TTI-101 reported today. These new data demonstrate encouraging signals across fibrosis, inflammatory markers and pulmona

    1/8/26 4:05:00 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights

    Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from Phase 1 study of next-generation STAT3 inhibitor, TTI-109, on track for H1 2026 HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). Preliminary results were announced on

    1/8/26 8:00:00 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tvardi Therapeutics downgraded by Barclays with a new price target

    Barclays downgraded Tvardi Therapeutics from Overweight to Equal Weight and set a new price target of $5.00

    10/14/25 8:43:30 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics downgraded by Raymond James

    Raymond James downgraded Tvardi Therapeutics from Outperform to Mkt Perform

    10/14/25 8:43:20 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Tvardi Therapeutics from Overweight to Neutral

    10/13/25 10:13:22 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    SEC Filings

    View All

    Tvardi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    1/16/26 6:04:33 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    12/18/25 5:21:05 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    11/19/25 6:44:08 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    Financials

    Live finance-specific insights

    View All

    Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

    Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in addition to nintedanib (OFEV®) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory

    10/13/25 7:30:00 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care